Emergent BioSolutions (EBS) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $1.14.
- Emergent BioSolutions' Debt to Equity fell 1254.96% to $1.14 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.14, marking a year-over-year decrease of 1254.96%. This contributed to the annual value of $1.37 for FY2024, which is 9990.72% up from last year.
- Per Emergent BioSolutions' latest filing, its Debt to Equity stood at $1.14 for Q3 2025, which was down 1254.96% from $1.25 recorded in Q2 2025.
- Emergent BioSolutions' Debt to Equity's 5-year high stood at $1.37 during Q4 2024, with a 5-year trough of $0.32 in Q4 2022.
- In the last 5 years, Emergent BioSolutions' Debt to Equity had a median value of $0.64 in 2023 and averaged $0.76.
- Its Debt to Equity has fluctuated over the past 5 years, first plummeted by 3565.22% in 2022, then soared by 14736.27% in 2024.
- Over the past 5 years, Emergent BioSolutions' Debt to Equity (Quarter) stood at $0.5 in 2021, then plummeted by 35.65% to $0.32 in 2022, then soared by 112.77% to $0.69 in 2023, then skyrocketed by 99.91% to $1.37 in 2024, then fell by 17.19% to $1.14 in 2025.
- Its Debt to Equity stands at $1.14 for Q3 2025, versus $1.25 for Q2 2025 and $1.2 for Q1 2025.